Comparative effectiveness of renin-angiotensin system inhibitors in hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Effectiveness Research

Background:

• Hypertension is a prevalent chronic condition in the USA.
• The renin-angiotensin system (RAS) is a key target for antihypertensive therapies.
• Primary RAS blockade strategies include direct renin inhibitors, ACEIs, and ARBs.

Purpose of the Study:

• To summarize a direct comparative effectiveness review of trials comparing antihypertensive medications.
• To evaluate the comparative effectiveness and safety of ACEIs, ARBs, and direct renin inhibitors in patients with hypertension.

Main Methods:

• Systematic review and meta-analysis of direct comparative trials.
• Focused on studies involving patients with hypertension.

Main Results:

• ACEIs and ARBs demonstrated similar effects on blood pressure and overall health outcomes.
• Angiotensin receptor blockers (ARBs) showed a lower incidence of ACE-induced cough and fewer adverse event-related withdrawals compared to ACEIs.
• Data comparing direct renin inhibitors with ACEIs or ARBs were limited, leaving their comparative role less defined.

Conclusions:

• ACEIs and ARBs represent effective and comparable therapeutic options for managing hypertension.
• ARBs offer a potential advantage in terms of tolerability due to reduced cough and adverse event withdrawals.
• Further research is needed to clarify the role of direct renin inhibitors in hypertension management.